PARP inhibitor Archives -

PROpel study backs Lynparza combo in first-line prostate cancer

https://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/

NICE says no to AZ’s Lynparza for prostate cancer

https://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

https://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/

Triple Negative Breast Cancer Drug Development Digital Summit

https://pharmaphorum.com/events/triple-negative-breast-cancer-drug-development-digital-summit/

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

https://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/

AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancer

https://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/

NICE backs Lynparza across the board for BRCA+ovarian cancer

https://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

Search